Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023 Mar 09, 2023 4:05pm EST
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference Mar 02, 2023 7:30am EST
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia Jan 30, 2023 7:00am EST
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations Dec 11, 2022 9:00am EST
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th Dec 07, 2022 4:05pm EST
Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib Nov 14, 2022 7:30am EST
